Company intelligence / Profile preview

Shenzhen Zhongke Ai Shen Pharmaceutical

Ownership: Private
Development stage: Other

Overview

Shenzhen Zhongke Ai Shen Pharmaceutical is conducting Phase 2 clinical trials for AS-1501, a TRAIL pathway-targeted therapy in acute-on-chronic liver failure (ACLF), and AS-1601, a PD-1 targeted agent in neoplasms. AS-1501 has shown safety and tolerability in Phase 1 trials; Phase 2 trials for ACLF are not yet recruiting as of June 2025.

Therapeutic areas: OncologyGastroenterology
Modalities: AntibodyOligonucleotideBiosimilarBiological products
Industry: Biotech

Drug pipeline

7 assets

AS1501

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Shenzhen Zhongke Ai Shen Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen Zhongke Ai Shen Pharmaceutical.